Asset
Vociprotafib
Revolution Medicines Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05054725 | phase2 | completed | 2021-12-30 | 2024-07-03 | Revolution Medicines, Inc. | Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies |
| NCT03634982 | phase1 | unknown | 2018-09-28 | 2023-03-31 | Revolution Medicines, Inc. | Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors |
| NCT03989115 | phase1_2 | completed | 2019-07-02 | 2022-02-08 | Revolution Medicines, Inc. | Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC |
FDA applications (0)
This company has no applications containing this asset.